Login to Your Account

SCLC Still the 'Uglier Sister'

'Pico' De Buyout: Is Poniard Due SPEARing Post-ASCO?

By Randy Osborne

Monday, June 14, 2010
Among the "Best of ASCO 2010" trials was the failed Phase III study with picoplatin, Poniard Pharmaceuticals Inc.'s new platinum chemotherapy against small cell lung cancer. South San Francisco-based Poniard trotted out details from the experiment to mixed reviews, and whatever else the news did, it may have put the low-valued firm - which has hired Leerink Swann to pursue options - in position for a big-pharma takeover.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription